超越形态学:胸膜间皮瘤的形态分子分类探索
本文综述胸膜间皮瘤在基因组学与分子病理学方面的进展,指出仅凭组织形态学无法充分反映疾病的异质性,提出基于倍体、肿瘤微环境和甲基化等分子特征的形态分子分类框架,以改善诊断、预后和治疗策略。
要点
- TNM分期仍是胸膜间皮瘤最强的生存预测指标和指导治疗的关键参数。
- 组织学单独无法捕捉疾病全貌,导致诊断、预后和治疗策略欠佳。
- 基于倍体、肿瘤微环境和甲基化的形态分子分类有望克服当前临床挑战。
核心结论
- 新兴证据表明仅靠组织学无法充分捕捉胸膜间皮瘤的异质性,基于分子特征的形态分子分类有望改善诊断、预后和治疗。
研究设计与样本
- 本文为综述,汇总近年与组织学、倍体、肿瘤微环境和甲基化相关的分子发现,并讨论形态分子分类的潜力。
主要发现
- TNM分类仍是胸膜间皮瘤最强的生存预测指标和指导治疗的最重要参数之一。
- 现有文献多聚焦形态相关改变,分子、免疫组化、临床和血液生物标志物多在相关性框架下研究。
- 倍体、肿瘤微环境和甲基化等分子特征共同提供对患者间异质性的更全面理解。
临床怎么用
- 临床实践中仍应以TNM分期作为胸膜间皮瘤生存预测和治療决策的核心依据。
局限性
- 现有分子、免疫组化、临床和血液生物标志物研究多在相关性框架下进行,尚未形成成熟的形态分子分类体系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite recent advances in the treatment of pleural mesothelioma, it remains a challenging and heterogeneous disease, with limited options for patients. Survival rates have only marginally improved in the past years, highlighting the need for a better biological understanding of the disease for the translation into clinical practice. Although recent years have seen substantial progress in genomics and molecular pathology, much of the existing literature has focused on morphology-correlated changes, with molecular, immunohistochemical, clinical, and blood biomarkers largely studied in a correlative framework. Despite these efforts, TNM classification remains the most powerful predictor of survival and one of the most important parameters to guide therapy in clinical practice. However, emerging evidence reveals that histology alone fails to capture the full heterogeneity of the disease, leading to suboptimal diagnostic, prognostic, and therapeutic approaches. This review summarizes recent major molecular findings relating not only to histology but also ploidy, tumor microenvironment, and methylation-which together offer a more comprehensive understanding of interpatient heterogeneity. In light of these results, we discuss the potential for a new morpho-molecular classification based on these molecular findings to overcome the current clinical challenges. Future directions for the field are also proposed, including the potential for emerging technologies such as single-cell, spatial omics, and artificial intelligence to fill in the gaps of bulk studies and unveil clinically relevant information about pleural mesothelioma tumor heterogeneity.
引用
- Drevet G, Kalson L, Mangé L, et al. Moving Beyond Morphology: Toward a Morpho-Molecular Classification of Pleural Mesothelioma. J Thorac Oncol. 2026. PMID: 41718511. doi:10.1016/j.jtho.2026.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。